Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12612412-B2

Patent

Publication Date

2026-04-28

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Core Innovation

The disclosure relates to antiviral compounds represented by Formula (XXV) and pharmaceutically acceptable salts thereof, alongside a selection of specifically listed compounds. In Formula (XXV), substituents R14 and R4 are cyclopropyl or 1-fluorocyclopropyl, R24 is hydrogen, Cl, F, or optionally substituted methoxyl, and R3 is hydroxy. Substituents R41 through R45 encompass hydrogen, halogen, optionally substituted methyl, methoxy, or cyano, with alternatives for forming a fused 4- to 7-membered carbocyclic or heterocyclic ring.

The disclosed embodiments include heteroaryl amides possessing a stereochemically defined hydroxy- and trifluoromethyl-containing scaffold, such as furo[2,3-c]pyridine derivatives and substituted fluorophenyl cores, with preparation procedures [procedural detail omitted for safety]. Disclosed embodiments demonstrate antiviral activity against respiratory syncytial virus and human metapneumovirus in cell-based assays. Because background sections are omitted from the supplied content, the specific technical problem addressed by the invention is not explicitly described in patent.

Claims Coverage

The supplied claims identify two independent claims representing two inventive features directed to compounds and pharmaceutically acceptable salts thereof.

Formula (XXV) compounds

A compound represented by Formula (XXV), or a pharmaceutically acceptable salt thereof, wherein R14 and R4 are cyclopropyl or 1-fluorocyclopropyl; R24 is hydrogen, Cl, F, or optionally substituted methoxyl; R3 is hydroxy; and R41, R42, R43, R44, and R45 are independently selected from hydrogen, halogen, optionally substituted methyl, optionally substituted methoxy, and —CN, with alternatives wherein R42 and R43, or R41 and R42, form a fused 4- to 7-membered carbocyclic or heterocyclic ring with their attached carbon atoms.

Selection of listed compounds

A compound selected from the specifically listed or depicted compounds set forth in the claim, or a pharmaceutically acceptable salt thereof.

The two independent claims cover the defined Formula (XXV) structural class and an enumerated selection of listed compounds, including their pharmaceutically acceptable salts, with dependent claims addressing pharmaceutical compositions and antiviral methods.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment or prevention of respiratory syncytial virus (RSV) infection using a claimed compound or a pharmaceutically acceptable salt thereof.

Treatment or prevention of human metapneumovirus (HMPV) infection using a claimed compound.

Treatment of RSV infection together with influenza using a claimed compound or a pharmaceutically acceptable salt thereof in combination with an anti-influenza agent.

Pharmaceutical compositions comprising a claimed compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, or excipient, including delivery forms such as inhalers and nebulizers.

Combinations of the described compounds with anti-inflammatory agents.

Cell-based screening result reporting antiviral activity of disclosed compounds against RSV-A and HMPV.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.